BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, released an update from Chairman Richard Staelin, PhD, highlighting the company's first small profit in calendar year 2025, achieved through cost controls and revenue initiatives. The company reported increased monthly sales in both over-the-counter and professional markets, driven by targeted advertising campaigns and strategic partnerships.
Staelin noted that the company relocated its offices and reduced staff to align with operational needs. These efforts, combined with advertising campaigns directed at medical professionals and Generation X consumers, have strengthened awareness of RecoveryRx, a non-opioid pain management device. The company is also pursuing a clinical trial partner for RecoveryRx, aiming to qualify for reimbursement under the federal NO PAIN Act, which could boost adoption in surgical settings.
A key milestone is the progress with Electrome Corporation, which placed an initial purchase order under a supply agreement. Manufacturing is underway, and Electrome is planning a commercial launch of BioElectronics' pulsed shortwave therapy products. This partnership is part of a broader strategy that includes clinical development, professional outreach, and international opportunities.
Internationally, the company continues arbitration proceedings in Singapore against a former distributor for breach of contract, aiming to protect intellectual property and shareholder interests. Despite the challenges, Staelin expressed optimism about the growing interest in drug-free pain management solutions and the company's position in the electroceutical market.
The update underscores the importance of non-opioid alternatives amid the opioid crisis. BioElectronics' progress could provide healthcare providers and patients with more options for pain management, potentially reducing reliance on opioids. However, the company faces risks typical of emerging medical technology firms, including lengthy arbitration and reliance on partnerships.
Forward-looking statements in the release caution that actual results may differ materially due to known and unknown risks. The company does not undertake to update these statements except as required by law.
